Hinokitiol
Based on 8 publication(s) in Google Scholar
Hinokitiol is a component of essential oils isolated from Chymacyparis obtusa, reduces Nrf2 expression, and decreases DNMT1 and UHRF1 mRNA and protein expression, with anti-infective, anti-oxidative, and anti-tumor activities.
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 499-44-5
- Formula: C10H12O2
- Molecular Weight:164.20
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Hinokitiol
More- Phytomedicine. 2025 Feb 5:139:156472. [Abstract]
- Eur J Pharmacol. 2024 Mar 5:966:176340. [Abstract]
- Int Immunopharmacol. 2021 Jul:96:107619. [Abstract]
- Sci Rep. 2025 Jan 27;15(1):3346. [Abstract]
- Cell Stress Chaperones. 2022 Nov;27(6):703-715. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Research Square Print. 2022 Jul.
- Oxid Med Cell Longev. 2021 Feb 10:2021:6670497. [Abstract]
All DNA Methyltransferase Isoforms
More
Biological Activity
|
DNMT1 |
Nrf2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BXPC-3 | GI50 |
19 μM
Compound: beta-tj
|
Cytotoxicity against human BxPC3 cells after 72 hrs by MTS assay
Cytotoxicity against human BxPC3 cells after 72 hrs by MTS assay
|
[PMID: 24900743] |
| Ehrlich | IC50 |
0.6 μg/mL
Compound: Hinokitiol
|
Cytotoxicity against mouse Ehrlich cells after 72 hrs by MTT assay
Cytotoxicity against mouse Ehrlich cells after 72 hrs by MTT assay
|
[PMID: 11975498] |
| FM3A | IC50 |
1.1 μM
Compound: 1
|
Inhibit growth of FM3A cells by 50%
Inhibit growth of FM3A cells by 50%
|
[PMID: 1732542] |
| G-361 | IC50 |
8.98 μM
Compound: beta-Thujaplicin
|
Competitive inhibition of tyrosinase in human G-361 cells incubated for 10 mins measured for 2 hrs by MBTH-based spectrophotometry
Competitive inhibition of tyrosinase in human G-361 cells incubated for 10 mins measured for 2 hrs by MBTH-based spectrophotometry
|
[PMID: 25288494] |
| HCT-116 | GI50 |
6.92 μM
Compound: beta-tj
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
|
[PMID: 24900743] |
| HCT-116 | IC50 |
4.5 μM
Compound: 1, Hinokitiol, beta-thujaplicin
|
Cytotoxicity against human HCT116 cells after 24 to 72 hrs
Cytotoxicity against human HCT116 cells after 24 to 72 hrs
|
[PMID: 24308647] |
| HL-60 | IC50 |
0.3 μg/mL
Compound: Hinokitiol, beta-thujaplicin
|
Cytotoxicity against Homo sapiens (human) HL60
Cytotoxicity against Homo sapiens (human) HL60
|
[PMID: 15187442] |
| HT-22 | EC50 |
4.8 μM
Compound: beta-thujaplicin
|
Neuroprotective activity against glutamate-mediated oxidative stress-induced cell death in mouse HT22 cells assessed as survival after 24 hrs by MTT assay
Neuroprotective activity against glutamate-mediated oxidative stress-induced cell death in mouse HT22 cells assessed as survival after 24 hrs by MTT assay
|
[PMID: 20045220] |
| HuT78 | GI50 |
4.99 μM
Compound: beta-tj
|
Cytotoxicity against human HUT78 cells after 72 hrs by MTS assay
Cytotoxicity against human HUT78 cells after 72 hrs by MTS assay
|
[PMID: 24900743] |
| Jurkat | GI50 |
1.1 μM
Compound: beta-tj
|
Cytotoxicity against human Jurkat cells after 72 hrs by MTS assay
Cytotoxicity against human Jurkat cells after 72 hrs by MTS assay
|
[PMID: 24900743] |
| K562 | IC50 |
0.3 μg/mL
Compound: Hinokitiol, beta-thujaplicin
|
Cytotoxicity against Homo sapiens (human) K562
Cytotoxicity against Homo sapiens (human) K562
|
[PMID: 15187442] |
| KB | IC50 |
3.5 μM
Compound: 1
|
Inhibit growth of KB cells by 50%
Inhibit growth of KB cells by 50%
|
[PMID: 1732542] |
| SW-620 | IC50 |
4.4 μM
Compound: 1, Hinokitiol, beta-thujaplicin
|
Cytotoxicity against human SW620 cells after 24 to 72 hrs
Cytotoxicity against human SW620 cells after 24 to 72 hrs
|
[PMID: 24308647] |
| T98G | IC50 |
152.5 μM
Compound: Hinokitiol
|
Inhibition of cell viability in human T98G cells incubated for 24 hrs by MTT assay
Inhibition of cell viability in human T98G cells incubated for 24 hrs by MTT assay
|
[PMID: 39241669] |
| U-87MG ATCC | IC50 |
316.5 μM
Compound: Hinokitiol
|
Inhibition of cell viability in human U-87 MG cells incubated for 24 hrs by MTT assay
Inhibition of cell viability in human U-87 MG cells incubated for 24 hrs by MTT assay
|
[PMID: 39241669] |
In U87MG and T98G glioma cell lines, hinokitiol demonstrates a dose-dependent decrease in viability, with IC50 values of 316.5 ± 35.5 and 152.5 ± 25.3 μM, respectively. Hinokitiol represses ALDH activity and self-renewal ability in glioma stem cells, and inhibits in vitro oncogenicity. Hinokitiol also reduces Nrf2 expression in glioma stem cells in a dose-dependent manner[1]. Hinokitiol (0-100 μM) inhibits colon cancer cell growth in a dose- and time-dependent manner. Hinokitiol (5, 10 μM) decreases DNMT1 and UHRF1 mRNA and protein expression, and increases TET1 expression via enhancement of 5hmC level in HCT-116 cells. Furthermore, hinokitiol reduces methylation status and restores mRNA expression of MGMT, CHST10, and BTG4 genes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 499-44-5
-
Appearance Solid
-
Molecular Weight 164.20
-
Formula C10H12O2
-
Color Off-white to yellow
-
SMILES
O=C1C(O)=CC(C(C)C)=CC=C1
-
Synonyms
β-Thujaplicin
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Hinokitiol ameliorates MASH in mice by therapeutic targeting of hepatic Nrf2 and inhibiting hepatocyte ferroptosis. [Abstract]2025 Feb 5:139:156472. PMID: 39922149 -
Eur J Pharmacol
Hinokitiol protects gastric injury from ethanol exposure via its iron sequestration capacity. [Abstract]2024 Mar 5:966:176340. PMID: 38244759 -
Int Immunopharmacol
Hinokitiol inhibits RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced bone loss in vivo. [Abstract]2021 Jul:96:107619. PMID: 33831806 -
Sci Rep
UHRF1 promotes epithelial-mesenchymal transition mediating renal fibrosis by activating the TGF-β/SMAD signaling pathway. [Abstract]2025 Jan 27;15(1):3346. PMID: 39870702 -
Cell Stress Chaperones
ALDH3B1 protects interfollicular epidermal cells against lipid peroxidation via the NRF2 pathway. [Abstract]2022 Nov;27(6):703-715. PMID: 36327089 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
-
Oxid Med Cell Longev
Ferroportin-Dependent Iron Homeostasis Protects against Oxidative Stress-Induced Nucleus Pulposus Cell Ferroptosis and Ameliorates Intervertebral Disc Degeneration In Vivo. [Abstract]2021 Feb 10:2021:6670497. PMID: 33628376
Solvent & Solubility
DMSO : 100 mg/mL (609.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (15.23 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (15.23 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 10 mg/mL (60.90 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
U87MG and T98G glioma cells are cultured in Dulbecco's modified Eagle's medium with Ham's F12 medium (DMEM/F-12) containing 10% fetal bovine serum. Cell viability is determined using MTT to evaluate the cytotoxicity of hinokitiol. Cells are seeded in 24-well plates (1×105 cells/well) in the presence of various concentration of hinokitiol or vehicle at 37°C for 24 h followed by incubation with MTT reagent. The blue formazan crystals of viable cells are dissolved in DMSO and then evaluated spectrophotometrically at 570 nm. DMSO-treated group is set as 100%, and data are presented as percentage of DMSO control. IC50 values are calculated by the GraFit software.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ouyang WC, et al. Hinokitiol suppresses cancer stemness and oncogenicity in glioma stem cells by Nrf2 regulation. Cancer Chemother Pharmacol. 2017 Aug;80(2):411-419. [Content Brief]
[2]. Seo JS, et al. Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells. BMC Cell Biol. 2017 Feb 27;18(1):14. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.0901 mL | 30.4507 mL | 60.9013 mL | 152.2534 mL |
| 5 mM | 1.2180 mL | 6.0901 mL | 12.1803 mL | 30.4507 mL | |
| 10 mM | 0.6090 mL | 3.0451 mL | 6.0901 mL | 15.2253 mL | |
| 15 mM | 0.4060 mL | 2.0300 mL | 4.0601 mL | 10.1502 mL | |
| 20 mM | 0.3045 mL | 1.5225 mL | 3.0451 mL | 7.6127 mL | |
| 25 mM | 0.2436 mL | 1.2180 mL | 2.4361 mL | 6.0901 mL | |
| 30 mM | 0.2030 mL | 1.0150 mL | 2.0300 mL | 5.0751 mL | |
| 40 mM | 0.1523 mL | 0.7613 mL | 1.5225 mL | 3.8063 mL | |
| 50 mM | 0.1218 mL | 0.6090 mL | 1.2180 mL | 3.0451 mL | |
| 60 mM | 0.1015 mL | 0.5075 mL | 1.0150 mL | 2.5376 mL | |
| 80 mM | 0.0761 mL | 0.3806 mL | 0.7613 mL | 1.9032 mL | |
| 100 mM | 0.0609 mL | 0.3045 mL | 0.6090 mL | 1.5225 mL |